Diasorin Inc.

Diasorin Inc., a Minnesota-based foreign-owned manufacturer and subsidiary of Italian-based Diasorin S.P.A., supplies chemiluminescence immunoassay analyzers, diagnostic reagents, consumables, and related technical services to federal healthcare agencies as a prime contractor across 464 awards with combined potential value of $131.7 million. The vendor operates exclusively as a prime contractor (100% of awards) with no subcontractor footprint, competing on full-and-open basis without socioeconomic set-asides.

Diasorin's core capability centers on the LIAISON XL and LIAISON XS chemiluminescence immunoassay analyzer platforms and associated consumables for infectious disease diagnostics—tuberculosis, COVID-19, varicella, cytomegalovirus, Herpes Simplex Virus, and HIV—alongside preventative maintenance, equipment leasing, operator training, and laboratory information system integration services. Representative work includes a $4.614 million firm fixed-price cost-per-kit agreement with the Defense Health Agency (Brooke Army Medical Center, Fort Sam Houston, Texas) for chemiluminescence immunoassay reagents through September 2030; a $2.273 million purchase order with the Department of Veterans Affairs (VISN 22) for immunoassay reagents supporting five California and Arizona VA facilities through September 2026; a $1.997 million Defense Health Agency purchase order for reagents and analyzers at Fort Sill, Oklahoma (Army Medical Command) through September 2029; and a $1.487 million Defense Health Agency award for reagents and consumables at Tripler Army Medical Center through September 2026. Smaller orders range from $15,000 to $300,000 across supply, maintenance, and equipment delivery for specific VA facilities and military treatment centers.

The Defense Health Agency dominates Diasorin's potential-value ranking (31 awards, $19.7 million combined), followed by the Air Force Materiel Command ($16.5 million, 14 awards), the Centers for Disease Control and Prevention ($16 million, 15 awards), and the Department of Veterans Affairs VISN 22 ($13.8 million, 36 awards). The top five customer agencies account for 56% of combined potential value and 30% of award count. By volume, VISN 22 leads with 36 awards, followed by the Defense Health Agency (31 awards), Department of Army Medical Command (30 awards), VISN 17 (22 awards), and VISN 4 (20 awards). Concentration reflects dual positioning: the VA accounts for the largest customer footprint across 13 distinct VISNs with 100+ awards total, while the Defense Health Agency and military treatment facilities anchor the highest-value single awards.

Diasorin holds or sits on multiple indefinite delivery vehicles and Federal Supply Schedule contracts. The $10 million Critical Analyzers, Laboratory (FSS-66-III) Federal Supply Schedule contract with the VA's VISN 12 (awarded April 2025, through March 2030) is the largest vehicle; it has generated delivery orders across VISN 5, VISN 4, and other networks for HIV testing kits, immunoassay equipment, and reagents. Five single-award IDIQs with various VA VISNs carry ceilings of $750,000 (VISN 23, through September 2026), $1.5 million (VISN 20, through July 2030), $1.754 million (VISN 9, through September 2029), $2 million (VISN 21, through September 2026), and $226,000 (VISN 10, through July 2027). The Defense Health Agency holds a $540,000 IDIQ for LIAISON XL test kits and supplies (through September 2030). Single-award BPAs with VISN 15 ($730,617, through January 2031) and VISN 17 ($474,659, through December 2030) support cost-per-test and infectious-disease diagnostic procurements. The Air Force Materiel Command blanket purchase agreement, established March 2021 and valued at $250,000, has supported BPA calls through October 2022. Task-order velocity across the top-five vehicles totals 65 task orders drawing $7.5 million in combined potential value, indicating active utilization.

Recent activity shows consistent quarterly award volume with 31 awards in FY2025 and 14 awards through August 2026 (the most recent award dated August 1, 2026, a $2.315 million BPA with VISN 2 for bacterial markers and infectious disease equipment through July 2027). Twenty-five awards with ultimate completion dates within the next twenty-four months carry combined potential value of $7.1 million, representing recompete exposure driven primarily by VISN 22 maintenance and service agreements, VISN 20 reagent supply contracts, and Air Force Materiel Command BPA calls scheduled to close by mid-2027. Work is performed nationwide at VA medical centers, military treatment facilities (Lewis McChord, Fort Sam Houston, Brooke Army Medical Center, Tripler), and Diasorin's Stillwater, Minnesota headquarters; some orders specify performance at CDC facilities, NIH Clinical Center, and Indian Health Service locations.

SCI-reported invoiced revenue for service contracts above the $150,000 threshold totals $20,000 in FY2024 across 0.1 FTEs, derived from a single maintenance-and-service contract (VISN 22, $661,800 ceiling) where Diasorin self-performed labor at a government-paid rate of $122.57 per hour with no subcontractor engagement. SCI coverage is minimal because Diasorin's footprint is dominated by goods (analyzers, reagents, consumables) and equipment purchases below or exempt from SCI reporting; this figure does not represent total federal services revenue. The vendor's corporate structure includes named subsidiaries Luminex Corp and Diasorin Molecular, LLC, both foreign-owned manufacturers, though no subsidiary-specific awards appear in the source portfolio.